**REIMBURSED DRUGS WITH ALTERNATIVE PAYMENT MODEL IN TURKEY**

**Oya Demir**1**, Ayşen Şentürk2, Rabia Kahveci**3

1 Boehringer Ingelheim, Turkey, 2 Polar Health Economics and Policy Consultancy, Turkey, 3Numune Research and Training Hospital

**OBJECTIVES:** Products with alternative payment model submission in Turkey, are evaluated by Alternative Reimbursement Committee. This committee had been founded in 2015, however has started its studies in 2016. The committee has been executing evaluations on financial-based models so far, yet, it has been declared that performance-based model implementation will also be evaluated henceforth. The purpose of this study is to analyze the products entering Turkish pharmaceutical market and reimbursed with alternative payment model in last two years.

**METHODS**: The study was undertaken from the Turkish health care payer perspective (SSI). An Excel sheet was formed to calculate the results and graphics. Resource utilization data were obtained from Social Security Institution web site and RxMediapharma.

**RESULTS:** With alternative payment model submission, 15 products in 2016, and 15 products in the first half of 2017, all in all 30 products in total got reimbursement via Alternative Reimbursement Committee decision.10 of these evaluated by payer invitation – Established/ innovative products not available on the market- whereas 20 of them by companies’ initiative. Average evaluation period for products that were previously supplied via International Pharmacy is 286 days, while first time applications take on an average of 399 days. Products reimbursed according to ATC code, respectively are; Anti-neoplastic and Immuno-modulating, Anti-infective for systemic use, Musculo-skeletal System, Alimentary Tract and Metabolism. These products licenced to the companies, respectively: Gen Pharmaceuticals, Abbvie, Gilead, BMS, Takeda, mostly taking share of Hepatitis C, Multiple Sclerosis, Malignant Melanoma therapeutic markets.

**CONCLUSIONS:** Alternative reimbursement submissions are in favour of payer related to budget constraints, whilst companies prefer to accelerate reimbursement process in Turkey.